GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Earnings per Share (Diluted)

Ionis Pharmaceuticals (MEX:IONS) Earnings per Share (Diluted) : MXN-44.23 (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Earnings per Share (Diluted)?

Ionis Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was MXN-18.71. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-44.23.

Ionis Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2024 was MXN-18.71. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-44.23.

Ionis Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was MXN-22.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-54.87.

During the past 3 years, the average EPS without NRIGrowth Rate was 2.80% per year.

During the past 13 years, Ionis Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 69.40% per year. The lowest was -117.40% per year. And the median was 1.80% per year.


Ionis Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Ionis Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Earnings per Share (Diluted) Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.83 -63.26 -4.10 -37.04 -43.45

Ionis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.94 -1.02 -16.26 -8.24 -18.71

Competitive Comparison of Ionis Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Ionis Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's PE Ratio falls into.



Ionis Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Ionis Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6217.429-0)/143.190
=-43.42

Ionis Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-2766.093-0)/148.593
=-18.62

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-44.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Ionis Pharmaceuticals  (MEX:IONS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ionis Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.